Pheochromocytoma Clinical Trial
Official title:
A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors
This is an ongoing prospective Phase II clinical trial evaluating the efficacy of 131I-MIBG for the treatment of patients with metastatic or unresectable pheochromocytoma and related tumors.
1. To assess the efficacy of high-dose 131I-MIBG in the treatment of patients with
malignant pheochromocytoma and related tumors, with the basis of this initial
examination being the percentage of patients in CR or PR, and the percentage of patients
without PD for 3 years after the initial administration on 131I-MIBG therapy.
2. To describe the response rate of malignant pheochromocytoma patients treated with
high-dose 131I-MIBG.
3. To describe the toxicity of high-dose 131I-MIBG in patients with malignant
pheochromocytoma.
4. To describe the overall survival and failure-free survival of malignant pheochromocytoma
patients treated with high-dose 131I-MIBG.
5. To determine the utility of using the serum level of Chromogranin A as a tumor marker
for patients with malignant pheochromocytoma.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
| Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
| Terminated |
NCT05948137 -
F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
|
||
| Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
| Active, not recruiting |
NCT00436735 -
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
| Recruiting |
NCT05069220 -
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
|
Early Phase 1 | |
| Recruiting |
NCT06062082 -
Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
|
||
| Recruiting |
NCT04573816 -
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
|
||
| Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
| Not yet recruiting |
NCT06045260 -
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
|
Phase 2 | |
| Completed |
NCT00001147 -
Blood Sampling for Neurochemical and Genetic Testing
|
N/A | |
| Terminated |
NCT00002947 -
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
Phase 1 | |
| Completed |
NCT00001229 -
Diagnosis and Treatment of Pheochromocytoma
|
N/A | |
| Completed |
NCT01967576 -
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
|
Phase 2 | |
| Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
| Recruiting |
NCT03206060 -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
|
Phase 2 | |
| Not yet recruiting |
NCT04788927 -
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
|
||
| Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|